Syntax Research, Inc. Lexicon Pharmaceuticals, Inc. Transaction History
Syntax Research, Inc.
- $148 Billion
- Q3 2024
A detailed history of Syntax Research, Inc. transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Syntax Research, Inc. holds 142 shares of LXRX stock, worth $103. This represents 0.0% of its overall portfolio holdings.
Number of Shares
142
Previous 142
-0.0%
Holding current value
$103
Previous $239,000
6.69%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding LXRX
# of Institutions
141Shares Held
238MCall Options Held
459KPut Options Held
133K-
Artal Group S.A. Luxembourg, N4136MShares$99.4 Million100.0% of portfolio
-
Siren, L.L.C. New York, NY38.9MShares$28.4 Million3.05% of portfolio
-
Orbimed Advisors LLC San Diego, CA11MShares$8.05 Million0.41% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$7.22 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.09MShares$5.91 Million0.0% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $138M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...